Business
Ocular Therapeutix™ Reports Fourth Quarter and Year-End 2021 Financial Results and Business Update
DEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg Recorded Net Quarterly Sales of $12.2 Million, Representing Year-Over-Year Growth of 77% Creating New
About this update from Ocular Therapeutix, Inc.
[{"type":"text","content":"\nDEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg Recorded Net Quarterly Sales of $12.2 Million, Representing Year-Over-Year Growth of 77%\n\nCreating New Business Unit Focused on Optimizing the Commercial Opportunity for DEXTENZA in the Office Setting\n\nCompleted Enrollment in U.S.-based Clinical Trial for OTX-TKI for the Treatment of Wet AMD; Data Anticipated in the Second Half of 2022\n\nConference Call to Discuss Fourth Quarter Results to be Held at 4:30 p.m. ET\n\n BEDFORD, Mass.--(BUSINESS WIRE)--\nOcular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported financial results for the quarter and year ended December 31, 2021, and provided updates on its ophthalmology pipeline.\n\n“Ocular has had another strong quarter and a productive year,” said Antony Mattessich, President and Chief Executive Officer. “Our commercialization of DEXTENZA® continues to ramp. We successfully expanded the DEXTENZA label and achieved durable reimbursement that will sustain DEXTENZA’s growth well into the future. The creation of a specialized business unit focusing solely on DEXTENZA in the office setting will allow us to build the DEXTENZA franchise beyond the surgical setting and also establish the necessary commercial infrastructure to support our innovative product pipeline. Our pipeline has progressed well. Recent data from our Australia-based OTX-TKI Phase 1 trial continues to support a product profile that we believe could become standard of care in the treatment of wet AMD. We plan to provide data from our U.S.-based Phase 1 clinical trial for OTX-TKI, which recently completed enrollment, later in the year. In the treatment of glaucoma, we are excited to have initiated our Phase 2 trial for OTX-TIC and we are actively screening subjects. In the treatment of dry eye disease, we continue to analyze the full data set from our Phase 2 studies in OTX-CSI and OTX-DED, and look forward to presenting the clinical-regulatory and manufacturing strategies for these programs. Overall, we made great progress and look forward to a busy 2022 that will further advance our strong position within ophthalmology.”\n\nRecent Business Updates\n\nThe U.S. Commercial Uptake of DEXTENZA. Net product revenue of D...